Lessons learned from a review of the development of selected vaccines

Pediatrics

Volumn 104, Issue 4 I, 1999, Pages 942-950

  Peter, Georges ^a,b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Immunization; Vaccine; Vaccine development; Vaccine research

Indexed keywords

CHICKENPOX VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VACCINE;

ARTICLE; CHICKENPOX; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INFANT; LICENSING; PRIORITY JOURNAL; TYPHOID FEVER; UNITED STATES; VACCINATION;

EID: 0032864108     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.104.4.942     Document Type: Article

References (57)

1. National Vaccine Advisory Committee. United States vaccine research: a delicate fabric of public and private collaboration. Pediatrics. 1997;100: 1015-1020
2. Levine MM. The legacy of Edward Jenner. Br Med J. 1996;312: 1177-11783
3. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases. The Jordan Report: Accelerated Development of Vaccines, 1998. Bethesda, MD: NIAID; 1998
4. Gregersen J. Vaccine development: the long road from initial idea to product licensure. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. New York, NY: Marcel Dekker; 1997: 1165-1183
5. Centers for Disease Control and Prevention. Food and Drug Administration approval of use of Haemophilus b conjugate vaccine for infants. MMWR Morb Mortal Wkly Rep. 1990;39:698-699
6. Centers for Disease Control and Prevention. Food and Drug Administration approval of use of a Haemophilus b conjugate vaccine for infants. MMWR Morb Mortal Wkly Rep. 1990;39:925-926
7. Centers for Disease Control and Prevention. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children. MMWR Morb Mortal Wkly Rep. 1993;42:296-298
8. Centers for Disease Control and Prevention. Typhoid immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 1990;39:1-5
9. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 1996;45:1-25
10. Rennels MB, Glass RI, Dennehy PH, US Rotavirus Vaccine Efficacy Group. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the National Multicenter Trial. Pediatrics. 1996;97:7-13
11. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338:1405-1412
12. Karron RA, Wright PF, Crowe JE, Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997;176:1428-1436
13. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89:405-421
14. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422-434
15. Levine MM, Barry EM. Inadvertent nontarget effects of live vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. New York, NY: Marcel Dekker; 1997:1179-1184
16. Benyesh-Melnick M, Melnick JL, Rawls WE, et al. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol. 1967;86:112-136
17. Simanjuntak CH, O'Hanley P, Punjabi NH, et al. The safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children. J Infect Dis. 1993;158:1169-1176
18. Wallis C, Melnick JL. Concentration of viruses from sewage by adsorption on millipore membranes. Bull WHO. 1967;36:219-225
19. Tacket CO, Mattheis M, Rennels MB. Initial clinical evaluation of new candidate vaccines: phase 1 and 2 clinical trials of safety, immunogenicity and preliminary efficacy. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. New York, NY: Marcel Dekker; 1997:35-46
20. Clemens JD, Naficy A, Rao MR. Long-term evaluation of vaccine protection: methodological issues for phase 3 trials and phase 4 studies. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. New York, NY: Marcel Dekker; 1997:47-67
21. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980;152:361-376
22. Levine MM, Levine OS. Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use. Lancet. 1997;350:1386-1392
23. Levine OS, Schwartz B. Economic analyses of vaccines and vaccination programs: evaluating the economic rationale for immunization. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. New York, NY: Marcel Dekker; 1997:69-78
24. Fraser DW, Geil CC, Feldman RA. Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol. 1974;100:29-34
25. Fraser DW, Darby CP, Koehler RE, Jacobs CF, Feldman RA. Risk factors in bacterial meningitis: Charleston County, South Carolina. J Infect Dis. 1973;127:271-277
26. Ryan CA, Hargrett-Bean NT, Blake PA. Salmonella typhi infections in the United States, 1975-1984: increasing role of foreign travel. Rev Infect Dis. 1989;II:1-8
27. Taylor DN, Pollard RA, Blake PA. Typhoid in the United States and risk to the international traveler. J Infect Dis. 1983;148:599-602
28. Jin S, Kilgore PE, Holman RC, Clarke MJ, Gangarosa EJ, Glass RI. Trends in hospitalizations for diarrhea in United States children from 1979 through 1992: estimates of the morbidity associated with rotavirus. Pediatr Infect Dis J. 1996;15:397-404
29. Smith JC, Haddix AC, Teutsch SM, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics. 1995;96:609-615
30. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis. 1996;174(suppl 1):S5-S11
31. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr. 1994;124: 869-874
32. Hay JW, Daum RS. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Pediatr Infect Dis J. 1990;9:246-252
33. Kapikian AZ, Flores J, Vesikari T, et al. Recent advances in development of a rotavirus vaccine for prevention of severe diarrheal illness of infants and young children. Adv Exp Med Biol. 1991;310:255-264
34. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis. 1996;174(suppl 1):S65-S72
35. Levine MM, Ferreccio C, Black RE, Germanier R, Chilean Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987;1:1049-1052
36. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis. 1989;159:766-769
37. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 1990;336:891-894
38. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature. 1984;307:178-180
39. Hilleman MR. Yeast recombinant hepatitis B vaccine. Infection. 1987;15: 3-7
40. Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis. 1996;173:450-453
41. Gershon AA. Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis. 1995;10:93-124
42. Gershon AA. Varicella vaccine: its past, present and future. Pediatr Infect Dis J. 1995;14:742-744
43. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three year results. J Infect Dis. 1982;145:292-296
44. Wenger JD, Heath PT, Moxon R, Booy R. Epidemiological impact of conjugate vaccines against invasive disease caused by Haemophilus influenzae type b. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. New York, NY: Marcel Dekker; 1997:489-502
45. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993; 269:221-226
46. Daum RS, Marcuse EK, Giebink GS, et al. Haemophilus influenzae type b vaccines: lessons from the past. Pediatrics. 1988;81:893-897
47. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 1998;351: 356-361
48. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet. 1995; 345:1071-1074
49. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637-641
50. Feeney M, Ciegg A, Winwood P, Snook J, East Dorset Gastroenterology Group. A case-control study of measles vaccination and inflammatory bowel disease. Lancet. 1997;350:764-766
51. Chen RT, DeStefano F. Vaccine adverse events: casual or coincidental? Lancet. 1998;351:611-612
52. Thomas DR, Salmon RL, King J. Rates of first measles-mumps-rubella immunisation in Wales (UK). Lancet. 1998;351:1927
53. De Quadros CA, Olive JM, Hersh BS, et al. Measles elimination in the Americas. Evolving strategies. JAMA. 1996;275:224-229
54. Watson JC, Redd SC, Rhodes PH, Hadler SC. The interruption of transmission of indigenous measles in the United States during 1993. Pediatr Infect Dis J. 1998;17:363-367
55. Peltola H, Davidkin I, Valle M, et al. No measles in Finland. Lancet. 1997;350:1364-1365
56. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 1994;331:1397-1402
57. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Task Force on Safer Childhood Vaccines. Final report and recommendations. Bethesda, MD: NIAID 1998